Journal Article

Increased expression of IFI16 predicts adverse prognosis in multiple myeloma

Huang, Wenhui, Liu, Yan, Zeng Tiansheng, Si Chaozeng, Zhong Qingfu, Fu, Lin, Huang Zeyong, Qian Tingting, Cui Longzhen, Deng Cong, Zhu, Pei

2021

Overview

Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells and does not have sufficient prognostic indicators. Interferon gamma inducible protein 16 (IFI16) plays a crucial role in B-cell differentiation. Several studies have shown that IFI16 predicted prognosis in many cancers. However, the relationship between MM prognosis and IFI16 expression has not been studied. In our study, we analyzed the prognostic role of IFI16 expression and explored the possible mechanism in MM progression by using 4498 myeloma patients and 52 healthy donors from 13 independent gene expression omnibus (GEO) datasets. The IFI16 expression increased with myeloma progression, ISS stage, 1q21 amplification, and relapse (all P < 0.01). MM patients with higher IFI16 expression had shorter survival in six datasets (all P < 0.05). Furthermore, multivariate analysis indicated that enhanced IFI16 expression was an independent poor prognostic factor for EFS and OS (P = 0.007, 0.009, respectively). And PPI, GO, KEGG, and GSEA also confirmed that IFI16 promoted MM progression by participating in tumor-related pathways. In conclusion, our study confirmed that IFI16 was a poor prognostic biomarker in MM.

• Publisher: Nature Publishing Group
• Subject: Cell differentiation / Gene expression / Interferon / Lymphocytes B / Malignancy / Medical prognosis / Multiple myeloma / Multivariate analysis / Plasma cells / Prognosis